See more : enGene Holdings Inc. Warrants (ENGNW) Income Statement Analysis – Financial Results
Complete financial analysis of Milestone Pharmaceuticals Inc. (MIST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Milestone Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Exchange Bankshares, Inc. (EXCH) Income Statement Analysis – Financial Results
- DigitalBridge Group, Inc. (DBRG-PH) Income Statement Analysis – Financial Results
- Três Tentos Agroindustrial S/A (TTEN3.SA) Income Statement Analysis – Financial Results
- Perpetual Limited (PPTTF) Income Statement Analysis – Financial Results
- Akwaaba Mining Ltd. (CPKOF) Income Statement Analysis – Financial Results
Milestone Pharmaceuticals Inc. (MIST)
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.00M | 5.00M | 15.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 480.00K | 0.00 | 376.00K | 236.00K | 10.00K | 8.00K |
| Gross Profit | 1.00M | 4.52M | 15.00M | -376.00K | -236.00K | -10.00K | -8.00K |
| Gross Profit Ratio | 100.00% | 90.40% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31.05M | 39.83M | 38.67M | 34.49M | 41.99M | 16.85M | 5.64M |
| General & Administrative | 15.93M | 15.72M | 12.40M | 10.29M | 7.00M | 3.05M | 1.50M |
| Selling & Marketing | 15.11M | 9.10M | 7.00M | 5.94M | 8.89M | 3.92M | 1.13M |
| SG&A | 31.05M | 24.81M | 19.40M | 16.22M | 15.90M | 6.97M | 2.63M |
| Other Expenses | 0.00 | 0.00 | 7.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 62.10M | 64.64M | 58.07M | 50.71M | 57.88M | 23.82M | 8.27M |
| Cost & Expenses | 62.10M | 64.64M | 58.07M | 50.71M | 57.88M | 23.82M | 8.27M |
| Interest Income | 3.97M | 1.25M | 220.00K | 726.00K | 2.60M | 711.00K | 186.00K |
| Interest Expense | 2.55M | 0.00 | 0.00 | 726.00K | 2.60M | 0.00 | 0.00 |
| Depreciation & Amortization | 92.00K | 480.00K | 362.00K | 376.00K | 236.00K | 10.00K | 8.00K |
| EBITDA | -56.85M | -58.36M | -42.98M | -50.71M | -57.88M | -23.36M | -8.26M |
| EBITDA Ratio | -5,684.50% | -1,192.84% | -286.53% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -61.10M | -59.64M | -43.07M | -50.71M | -57.88M | -23.82M | -8.27M |
| Operating Income Ratio | -6,109.80% | -1,192.84% | -287.15% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.41M | 1.25M | 220.00K | 726.00K | 2.60M | 711.00K | 186.00K |
| Income Before Tax | -59.69M | -58.39M | -42.85M | -49.98M | -55.29M | -23.11M | -8.08M |
| Income Before Tax Ratio | -5,968.50% | -1,167.76% | -285.69% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.25M | -220.00K | -17.00K | -56.00K | 74.00K | 4.00K |
| Net Income | -59.69M | -57.13M | -42.63M | -49.97M | -55.23M | -23.19M | -8.09M |
| Net Income Ratio | -5,968.50% | -1,142.68% | -284.22% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.39 | -1.35 | -1.02 | -1.70 | -3.50 | -0.98 | -0.34 |
| EPS Diluted | -1.39 | -1.35 | -1.02 | -1.70 | -3.50 | -0.98 | -0.34 |
| Weighted Avg Shares Out | 42.96M | 42.45M | 41.83M | 29.34M | 15.78M | 23.65M | 23.65M |
| Weighted Avg Shares Out (Dil) | 42.96M | 42.45M | 41.83M | 29.34M | 15.78M | 23.65M | 23.65M |
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright
Milestone Pharmaceuticals Inc. (MIST) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MIST's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden...
Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025 NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025
Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China
MONTREAL and CHARLOTTE, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced its licensing partner, Ji Xing Pharmaceuticals Ltd, released positive topline results from...
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors...
Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
– NDA for CARDAMYST™ in PSVT accepted by FDA in 2Q 2024; PDUFA in March 2025 – Cash of $83.3 million as of June 30, 2024 expected to fund operations into 2026 – Stuart Duty and Andrew Saik Appointed as Independent Board Directors...
4 Stocks Under $5 To Buy Now
Are you looking for stocks to buy with low price tags?
Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024
MONTREAL and CHARLOTTE, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will host Part I of its virtual investor...
Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference
MONTREAL and CHARLOTTE, N.C., May 31, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in the Jefferies Global Healthcare Conference being held in New York City, NY from June 4-6,...
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™
MONTREAL and CHARLOTTE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the United States Food and Drug Administration (FDA) accepted the...
Brokers Set Expectations for Milestone Pharmaceuticals Inc.’s Q2 2024 Earnings (NASDAQ:MIST)
Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Free Report) – Investment analysts at HC Wainwright boosted their Q2 2024 earnings per share (EPS) estimates for Milestone Pharmaceuticals in a report released on Thursday, May 16th. HC Wainwright analyst P. Trucchio now anticipates...
Source: https://incomestatements.info
Category: Stock Reports